What is KeyCorp's Forecast for Bio-Techne Q3 Earnings?

Bio-Techne Co. (NASDAQ:TECH - Free Report) - Equities research analysts at KeyCorp issued their Q3 2025 earnings per share estimates for shares of Bio-Techne in a report released on Tuesday, April 8th. KeyCorp analyst P. Knight anticipates that the biotechnology company will post earnings per share of $0.44 for the quarter. KeyCorp has a "Sector Weight" rating on the stock. The consensus estimate for Bio-Techne's current full-year earnings is $1.67 per share. KeyCorp also issued estimates for Bio-Techne's Q4 2025 earnings at $0.43 EPS.

Bio-Techne (NASDAQ:TECH - Get Free Report) last posted its quarterly earnings results on Wednesday, February 5th. The biotechnology company reported $0.35 EPS for the quarter, missing analysts' consensus estimates of $0.38 by ($0.03). Bio-Techne had a return on equity of 12.73% and a net margin of 13.22%.

A number of other equities analysts have also commented on the company. StockNews.com raised Bio-Techne from a "hold" rating to a "buy" rating in a research note on Friday, April 4th. Evercore ISI began coverage on shares of Bio-Techne in a research report on Tuesday, March 18th. They set an "outperform" rating and a $75.00 price objective for the company. Scotiabank boosted their target price on shares of Bio-Techne from $88.00 to $90.00 and gave the stock a "sector outperform" rating in a report on Thursday, February 6th. Robert W. Baird lowered Bio-Techne from an "outperform" rating to a "neutral" rating and dropped their price target for the stock from $88.00 to $68.00 in a research report on Wednesday, February 19th. Finally, Royal Bank of Canada upped their price objective on Bio-Techne from $79.00 to $80.00 and gave the company a "sector perform" rating in a research report on Thursday, February 6th. Five equities research analysts have rated the stock with a hold rating and five have given a buy rating to the company's stock. Based on data from MarketBeat.com, Bio-Techne presently has an average rating of "Moderate Buy" and an average price target of $81.25.

Remove Ads

Bio-Techne Price Performance

TECH stock traded down $1.47 during mid-day trading on Friday, hitting $51.07. The company had a trading volume of 1,295,257 shares, compared to its average volume of 1,185,822. The company has a market capitalization of $8.07 billion, a price-to-earnings ratio of 51.59, a P/E/G ratio of 2.88 and a beta of 1.45. The company has a 50-day moving average price of $60.87 and a 200 day moving average price of $69.34. The company has a quick ratio of 2.77, a current ratio of 3.94 and a debt-to-equity ratio of 0.14. Bio-Techne has a 12-month low of $46.44 and a 12-month high of $85.57.

Bio-Techne Announces Dividend

The business also recently announced a quarterly dividend, which was paid on Friday, February 28th. Shareholders of record on Monday, February 17th were paid a $0.08 dividend. The ex-dividend date was Friday, February 14th. This represents a $0.32 dividend on an annualized basis and a yield of 0.63%. Bio-Techne's dividend payout ratio is currently 24.24%.

Insider Transactions at Bio-Techne

In other Bio-Techne news, CEO Kim Kelderman sold 13,392 shares of the stock in a transaction dated Monday, January 27th. The shares were sold at an average price of $77.29, for a total transaction of $1,035,067.68. Following the transaction, the chief executive officer now directly owns 39,004 shares in the company, valued at $3,014,619.16. This represents a 25.56 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Amy E. Herr sold 1,860 shares of the business's stock in a transaction dated Friday, February 14th. The shares were sold at an average price of $65.96, for a total transaction of $122,685.60. Following the completion of the sale, the director now owns 1,976 shares of the company's stock, valued at approximately $130,336.96. This represents a 48.49 % decrease in their position. The disclosure for this sale can be found here. Corporate insiders own 3.90% of the company's stock.

Hedge Funds Weigh In On Bio-Techne

Large investors have recently bought and sold shares of the business. Vanguard Group Inc. increased its holdings in shares of Bio-Techne by 1.5% in the 4th quarter. Vanguard Group Inc. now owns 18,594,608 shares of the biotechnology company's stock valued at $1,339,370,000 after acquiring an additional 275,644 shares during the period. Price T Rowe Associates Inc. MD boosted its position in Bio-Techne by 13.1% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 10,654,267 shares of the biotechnology company's stock valued at $767,428,000 after purchasing an additional 1,229,954 shares in the last quarter. Ameriprise Financial Inc. grew its stake in Bio-Techne by 7.2% in the fourth quarter. Ameriprise Financial Inc. now owns 4,702,942 shares of the biotechnology company's stock valued at $338,756,000 after purchasing an additional 317,349 shares during the last quarter. Geode Capital Management LLC raised its holdings in Bio-Techne by 2.5% in the fourth quarter. Geode Capital Management LLC now owns 4,001,296 shares of the biotechnology company's stock worth $287,488,000 after purchasing an additional 98,660 shares in the last quarter. Finally, Invesco Ltd. lifted its position in shares of Bio-Techne by 10.4% during the fourth quarter. Invesco Ltd. now owns 3,820,464 shares of the biotechnology company's stock valued at $275,188,000 after buying an additional 358,756 shares during the last quarter. Institutional investors own 98.95% of the company's stock.

Bio-Techne Company Profile

Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research and clinical diagnostic markets in the United States, the United Kingdom, rest of Europe, Middle East, and Africa, Greater China, rest of Asia-Pacific, and internationally.